0001477932-26-002472
SEC filingVolitionRx received NYSE American acceptance of its compliance plan, granting until August 6, 2027 to regain listing standards.
On April 22, 2026, the NYSE American accepted VolitionRx's plan to regain compliance with continued listing standards, following a February 6, 2026 notice of non-compliance due to insufficient stockholders' equity. The company has until August 6, 2027 to meet the equity requirements under Sections 1003(a)(i)-(iii). During this period, the stock remains listed and traded on the NYSE American under symbol VNRX. The acceptance does not affect business operations or SEC reporting obligations. However, if VolitionRx fails to make progress or meet the deadline, delisting proceedings may be initiated, posing a significant risk to shareholders.